| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Lois A Lampson | |
| P2860 | cites work | Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. | Q51989383 |
| Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER-2 Positive Metastatic Breast Cancer | Q62581294 | ||
| Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment | Q78409843 | ||
| Primary central nervous system lymphoma | Q80523652 | ||
| Primary central nervous system lymphoma | Q80526856 | ||
| Genes that mediate breast cancer metastasis to the brain | Q24644008 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Recent advances in blood-brain barrier disruption as a CNS delivery strategy | Q31154008 | ||
| Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials | Q33293618 | ||
| Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma | Q33377067 | ||
| Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme | Q33518926 | ||
| Engineered CH2 domains (nanoantibodies). | Q33521668 | ||
| Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression | Q33547564 | ||
| Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors | Q33760569 | ||
| A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma | Q34007430 | ||
| Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas | Q34139432 | ||
| New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns | Q34445529 | ||
| The blood-brain barrier and cancer: transporters, treatment, and Trojan horses | Q34577796 | ||
| Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer | Q34624378 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 | ||
| Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors | Q36677197 | ||
| Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario | Q36714204 | ||
| Primary central nervous system lymphoma: biological aspects and controversies in management | Q36791323 | ||
| CNS complications of breast cancer: current and emerging treatment options | Q36853533 | ||
| Lessons learned in the development of targeted therapy for malignant gliomas. | Q36874488 | ||
| Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials | Q36885522 | ||
| FcRn: the neonatal Fc receptor comes of age. | Q36912134 | ||
| Is the blood-brain barrier relevant in metastatic germ cell tumor? | Q36913822 | ||
| Active targeting of brain tumors using nanocarriers | Q36918333 | ||
| Breast cancer brain metastases | Q36918681 | ||
| A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects | Q36959591 | ||
| Monoclonal antibodies for B-cell lymphomas: rituximab and beyond | Q37007354 | ||
| Biodistribution processes as underestimated confounders in translational stroke research | Q37066100 | ||
| Antiangiogenic therapy in malignant glioma: promise and challenge | Q37066217 | ||
| N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG. | Q37136734 | ||
| Adaptive design methods in clinical trials - a review | Q37153817 | ||
| Barriers in the brain: a renaissance? | Q37159965 | ||
| Blood-neural barrier: its diversity and coordinated cell-to-cell communication | Q37176627 | ||
| Invited article: inhibition of B cell functions: implications for neurology | Q37180011 | ||
| A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue | Q37183305 | ||
| HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? | Q37184721 | ||
| Managing premedications and the risk for reactions to infusional monoclonal antibody therapy | Q37202488 | ||
| Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge | Q37211521 | ||
| The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? | Q37267842 | ||
| New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? | Q37286235 | ||
| Vaccines for lymphomas: idiotype vaccines and beyond | Q37308370 | ||
| Immune therapy for cancer | Q37324793 | ||
| HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Q37325230 | ||
| Targeted therapy for neuro-oncology: reviewing the menu | Q37343654 | ||
| Drug interactions at the blood-brain barrier: fact or fantasy? | Q37362486 | ||
| Cancer therapy using tumor-associated antigens to reduce side effects | Q37466336 | ||
| Treatment of brain metastases in patients with HER2+ breast cancer | Q37577635 | ||
| Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. | Q37597698 | ||
| Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
| Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents | Q37665795 | ||
| Understanding and circumventing resistance to anticancer monoclonal antibodies. | Q37672125 | ||
| Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma | Q40177381 | ||
| Pathology of cerebral metastases | Q41123969 | ||
| Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer | Q44176007 | ||
| Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours | Q46230407 | ||
| Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. | Q46294074 | ||
| Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases | Q46490986 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme | Q48371520 | ||
| Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. | Q48412388 | ||
| HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report. | Q48479008 | ||
| Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab | Q48612753 | ||
| Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. | Q48770142 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| antibody | Q79460 | ||
| blood–brain barrier | Q221694 | ||
| brain tumor | Q233309 | ||
| non-Hodgkin lymphoma | Q1138590 | ||
| glioblastoma | Q282142 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 153-160 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Monoclonal Antibodies | Q6714645 |
| P1476 | title | Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | |
| P478 | volume | 3 |
| Q35266784 | (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients |
| Q35992488 | 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. |
| Q26748601 | An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica |
| Q48480477 | Anti-GITR therapy promotes immunity against malignant glioma in a murine model. |
| Q92489979 | Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality |
| Q91526319 | Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases |
| Q38729214 | Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications |
| Q37986999 | Cancer immunoediting in malignant glioma |
| Q44593682 | Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy. |
| Q36891034 | Depleting tumor-specific Tregs at a single site eradicates disseminated tumors |
| Q34553348 | Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. |
| Q40089704 | EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. |
| Q55317796 | Editorial: Immunotherapy for Tumor in the Brain: Insights From-and For-Other Tumor Sites. |
| Q35075446 | Emerging strategies for treating brain metastases from breast cancer |
| Q34673086 | Fluorescent affibody peptide penetration in glioma margin is superior to full antibody |
| Q60547811 | From Molecular to Clinical Radiation Biology of Glioblastoma |
| Q36851190 | Gliadel for brain metastasis. |
| Q38899910 | Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer. |
| Q36882972 | Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies |
| Q57490955 | Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease |
| Q26798402 | Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites |
| Q36516472 | Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach? |
| Q47234408 | Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. |
| Q34168363 | Introduction to current and future protein therapeutics: a protein engineering perspective |
| Q36371783 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. |
| Q26849243 | Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q47892833 | Molecular characterization of perivascular drainage pathways in the murine brain. |
| Q35498835 | Monitoring therapeutic monoclonal antibodies in brain tumor |
| Q36795953 | Nogo-A downregulation improves insulin secretion in mice. |
| Q37587716 | Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells |
| Q36383018 | Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. |
| Q48429982 | Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma |
| Q54313994 | Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. |
| Q38927027 | Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model |
| Q90413346 | Primary central nervous system marginal zone B-cell lymphoma arising from the dural meninges: A case report and review of literature |
| Q34749267 | Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging |
| Q36511945 | Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. |
| Q37281601 | Selective permeabilization of the blood-brain barrier at sites of metastasis |
| Q40893254 | Sudden hearing loss due to internal auditory canal metastasis of Her2-positive gastric cancer: A case report |
| Q39652258 | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions |
| Q27335251 | Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas |
| Q89597790 | The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors |
| Q34293163 | The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients |
| Q30576758 | The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments |
| Q35608531 | Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. |
| Q45072965 | Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer |
| Q64904346 | Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. |
| Q90245205 | Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival: A Case Report |
Search more.